Financhill
Sell
29

BBNX Quote, Financials, Valuation and Earnings

Last price:
$14.74
Seasonality move :
--
Day range:
$14.08 - $15.77
52-week range:
$13.64 - $24.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
269.4K
Avg. volume:
367.7K
1-year change:
--
Market cap:
$565.1M
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BBNX
Beta Bionics
$20.2M -$0.41 -- -- $26.43
BAX
Baxter International
$2.8B $0.61 -27.96% 589.09% $40.04
CATX
Perspective Therapeutics
-- -$0.30 -- -41.72% $15.58
PODD
Insulet
$577.7M $0.90 23.07% 6.17% $314.06
TNDM
Tandem Diabetes Care
$245M -$0.36 14.85% -7.32% $41.65
XTNT
Xtant Medical Holdings
$32.3M -$0.02 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BBNX
Beta Bionics
$14.68 $26.43 $565.1M -- $0.00 0% --
BAX
Baxter International
$34.59 $40.04 $17.7B 167.20x $0.17 2.66% 1.38x
CATX
Perspective Therapeutics
$2.59 $15.58 $175.1M -- $0.00 0% 13.99x
PODD
Insulet
$255.44 $314.06 $17.9B 44.12x $0.00 0% 9.11x
TNDM
Tandem Diabetes Care
$19.17 $41.65 $1.3B -- $0.00 0% 1.33x
XTNT
Xtant Medical Holdings
$0.48 $1.75 $66.8M -- $0.00 0% 0.55x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BBNX
Beta Bionics
-- 0.000 -- --
BAX
Baxter International
65.34% 0.281 88.33% 0.54x
CATX
Perspective Therapeutics
-- -3.661 -- --
PODD
Insulet
53.47% 1.510 7.6% 2.50x
TNDM
Tandem Diabetes Care
57.01% 2.440 14.62% 2.24x
XTNT
Xtant Medical Holdings
44.29% 0.232 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BBNX
Beta Bionics
-- -- -- -- -- --
BAX
Baxter International
$959M -$1M -3.07% -8.24% -15.29% $351M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
PODD
Insulet
$430.9M $109.3M 17.64% 43.11% 20.08% $91.7M
TNDM
Tandem Diabetes Care
$157.5M -$582K -16.17% -37.18% -0.01% -$38.8M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

Beta Bionics vs. Competitors

  • Which has Higher Returns BBNX or BAX?

    Baxter International has a net margin of -- compared to Beta Bionics's net margin of -18.6%. Beta Bionics's return on equity of -- beat Baxter International's return on equity of -8.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    BBNX
    Beta Bionics
    -- -- --
    BAX
    Baxter International
    34.84% -$1.00 $20.2B
  • What do Analysts Say About BBNX or BAX?

    Beta Bionics has a consensus price target of $26.43, signalling upside risk potential of 80.03%. On the other hand Baxter International has an analysts' consensus of $40.04 which suggests that it could grow by 15.76%. Given that Beta Bionics has higher upside potential than Baxter International, analysts believe Beta Bionics is more attractive than Baxter International.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBNX
    Beta Bionics
    5 1 0
    BAX
    Baxter International
    3 11 1
  • Is BBNX or BAX More Risky?

    Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Baxter International has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.696%.

  • Which is a Better Dividend Stock BBNX or BAX?

    Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.66% to investors and pays a quarterly dividend of $0.17 per share. Beta Bionics pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

  • Which has Better Financial Ratios BBNX or BAX?

    Beta Bionics quarterly revenues are --, which are smaller than Baxter International quarterly revenues of $2.8B. Beta Bionics's net income of -- is lower than Baxter International's net income of -$512M. Notably, Beta Bionics's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 1.38x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBNX
    Beta Bionics
    -- -- -- --
    BAX
    Baxter International
    1.38x 167.20x $2.8B -$512M
  • Which has Higher Returns BBNX or CATX?

    Perspective Therapeutics has a net margin of -- compared to Beta Bionics's net margin of --. Beta Bionics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BBNX
    Beta Bionics
    -- -- --
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About BBNX or CATX?

    Beta Bionics has a consensus price target of $26.43, signalling upside risk potential of 80.03%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 501.43%. Given that Perspective Therapeutics has higher upside potential than Beta Bionics, analysts believe Perspective Therapeutics is more attractive than Beta Bionics.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBNX
    Beta Bionics
    5 1 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is BBNX or CATX More Risky?

    Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

  • Which is a Better Dividend Stock BBNX or CATX?

    Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBNX or CATX?

    Beta Bionics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Beta Bionics's net income of -- is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Beta Bionics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 13.99x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBNX
    Beta Bionics
    -- -- -- --
    CATX
    Perspective Therapeutics
    13.99x -- -- -$15.1M
  • Which has Higher Returns BBNX or PODD?

    Insulet has a net margin of -- compared to Beta Bionics's net margin of 16.85%. Beta Bionics's return on equity of -- beat Insulet's return on equity of 43.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    BBNX
    Beta Bionics
    -- -- --
    PODD
    Insulet
    72.12% $1.39 $2.6B
  • What do Analysts Say About BBNX or PODD?

    Beta Bionics has a consensus price target of $26.43, signalling upside risk potential of 80.03%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 22.95%. Given that Beta Bionics has higher upside potential than Insulet, analysts believe Beta Bionics is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBNX
    Beta Bionics
    5 1 0
    PODD
    Insulet
    14 4 0
  • Is BBNX or PODD More Risky?

    Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

  • Which is a Better Dividend Stock BBNX or PODD?

    Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBNX or PODD?

    Beta Bionics quarterly revenues are --, which are smaller than Insulet quarterly revenues of $597.5M. Beta Bionics's net income of -- is lower than Insulet's net income of $100.7M. Notably, Beta Bionics's price-to-earnings ratio is -- while Insulet's PE ratio is 44.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 9.11x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBNX
    Beta Bionics
    -- -- -- --
    PODD
    Insulet
    9.11x 44.12x $597.5M $100.7M
  • Which has Higher Returns BBNX or TNDM?

    Tandem Diabetes Care has a net margin of -- compared to Beta Bionics's net margin of 0.27%. Beta Bionics's return on equity of -- beat Tandem Diabetes Care's return on equity of -37.18%.

    Company Gross Margin Earnings Per Share Invested Capital
    BBNX
    Beta Bionics
    -- -- --
    TNDM
    Tandem Diabetes Care
    55.71% $0.01 $612M
  • What do Analysts Say About BBNX or TNDM?

    Beta Bionics has a consensus price target of $26.43, signalling upside risk potential of 80.03%. On the other hand Tandem Diabetes Care has an analysts' consensus of $41.65 which suggests that it could grow by 117.27%. Given that Tandem Diabetes Care has higher upside potential than Beta Bionics, analysts believe Tandem Diabetes Care is more attractive than Beta Bionics.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBNX
    Beta Bionics
    5 1 0
    TNDM
    Tandem Diabetes Care
    8 10 0
  • Is BBNX or TNDM More Risky?

    Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.446, suggesting its more volatile than the S&P 500 by 44.616%.

  • Which is a Better Dividend Stock BBNX or TNDM?

    Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBNX or TNDM?

    Beta Bionics quarterly revenues are --, which are smaller than Tandem Diabetes Care quarterly revenues of $282.6M. Beta Bionics's net income of -- is lower than Tandem Diabetes Care's net income of $755K. Notably, Beta Bionics's price-to-earnings ratio is -- while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 1.33x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBNX
    Beta Bionics
    -- -- -- --
    TNDM
    Tandem Diabetes Care
    1.33x -- $282.6M $755K
  • Which has Higher Returns BBNX or XTNT?

    Xtant Medical Holdings has a net margin of -- compared to Beta Bionics's net margin of -10.04%. Beta Bionics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    BBNX
    Beta Bionics
    -- -- --
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About BBNX or XTNT?

    Beta Bionics has a consensus price target of $26.43, signalling upside risk potential of 80.03%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that Xtant Medical Holdings has higher upside potential than Beta Bionics, analysts believe Xtant Medical Holdings is more attractive than Beta Bionics.

    Company Buy Ratings Hold Ratings Sell Ratings
    BBNX
    Beta Bionics
    5 1 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is BBNX or XTNT More Risky?

    Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

  • Which is a Better Dividend Stock BBNX or XTNT?

    Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BBNX or XTNT?

    Beta Bionics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Beta Bionics's net income of -- is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Beta Bionics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BBNX
    Beta Bionics
    -- -- -- --
    XTNT
    Xtant Medical Holdings
    0.55x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock